Out-of-Pocket Costs for Novel Guideline-Directed Diabetes Therapies Under Medicare Part D

JAMA Intern Med. 2020 Dec 1;180(12):1696-1699. doi: 10.1001/jamainternmed.2020.2922.

¹ Department of Medicine, University of California, San Francisco.
² Daniel K. Inouye College of Pharmacy, University of Hawaii at Hilo.
³ Pacific Health Research and Education Institute, Honolulu, Hawaii.
⁴ Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
⁵ Departments of Medicine, Health Policy, and Informatics, University of Minnesota School of Medicine, Minneapolis.
⁶ Department of Family Medicine and Community Health, John A. Burns School of Medicine, University of Hawaii, Honolulu.

Abstract

This study examines cost sharing for novel second-line diabetes treatment agents under Medicare Part D.